

Paper No. \_\_\_\_\_  
Date Filed: April 5, 2016

Filed on behalf of: Aventis Pharma S.A.

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**MYLAN LABORATORIES LIMITED**

**Petitioner,**

**v.**

**AVENTIS PHARMA S.A.**

**Patent Owner.**

---

Case IPR2016-00712  
U.S. Patent No. 8,927,592

---

**AVENTIS PHARMA S.A.**  
**MANDATORY NOTICES – 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, Aventis Pharma S.A. (the “Patent Owner”), as indicated by the assignment recorded at Reel/Frame 028992/0505 submits the following Mandatory Notices.

**Real Party-In-Interest (37 C.F.R. § 42.8 (b)(1)):**

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the real party-in-interest is Aventis Pharma S.A. (the “Patent Owner”). Sanofi, the ultimate parent company of Aventis Pharma S.A., and Sanofi-Aventis U.S. LLC, an affiliate of Aventis Pharma S.A. are also real parties-in-interest.

**Related Matters (37 C.F.R. § 42.8 (b)(2)):**

On May 15, 2015, Patent Owner, along with Sanofi-Aventis U.S. LLC and Sanofi (collectively “Sanofi”) filed a complaint averring that Petitioner’s Abbreviated New Drug Application (“ANDA”) No. 207381 concerning a proposed drug product, cabazitaxel injection [60 mg/1.5 mL] [40 mg/mL], infringes U.S. Patent No. 8,927,592 (“the ’592 patent”) under 35 U.S.C. § 271(e)(2). That lawsuit is pending in the United States District Court for the District of New Jersey and is captioned: *Sanofi-Aventis U.S. LLC et al. v. Mylan Laboratories Limited*, Civil Action No. 15-03392 (MAS)(LHG). Sanofi also filed additional complaints alleging infringement of the ’592 patent that are all pending in the United States District Court for the District of New Jersey and are captioned: *Sanofi-Aventis U.S. LLC et al. v. Fresenius Kabi USA, LLC*, C. A. No. 15-02631 (MAS)(LHG); *Sanofi-*

*Aventis U.S. LLC et al. v. Accord Healthcare, Inc.*, C. A. No. 15-02520 (MAS)(LHG); *Sanofi-Aventis U.S. LLC et al. v. BPI Labs, LLC et al.*, C. A. No. 15-02521 (MAS)(LHG); *Sanofi-Aventis U.S. LLC et al. v. Apotex Corp. et al.*, C. A. No. 15-01835 (MAS)(LHG); *Sanofi-Aventis U.S. LLC et al. v. Breckenridge Pharmaceutical, Inc.*, C. A. No. 15-01836 (MAS)(LHG); *Sanofi-Aventis U.S. LLC et al. v. Actavis LLC et al.*, C. A. No. 15-03107 (MAS)(LHG); *Sanofi-Aventis U.S. LLC et al. v. Dr. Reddy's Laboratories, Inc. et al.*, C. A. No. 15-02522 (MAS)(LHG); and *Sanofi-Aventis U.S. LLC et al. v. Glenmark Pharmaceuticals, Inc., USA et al.*, C. A. No. 15-02523 (MAS)(LHG). Also, the following patent applications claim the benefit of the priority of the filing date of the subject patent: U.S. Patent Application Nos. 14/575,566 and 14/575,578.

**Designation of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)):**

Lead counsel is Dominick A. Conde (Reg. No. 33,856). William E. Solander, Jason A. Leonard, and Whitney L. Meier (Reg. No. 69,923) are designated as back-up counsel. William E. Solander and Jason A. Leonard require *pro hac vice* admission to appear in this proceeding.

A power of attorney from Aventis Pharma S.A. is being submitted with this Notice.

**Service Information (37 C.F.R. § 42.8(b)(4)):**

Aventis Pharma S.A. may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Dominick A. Conde

FITZPATRICK, CELLA, HARPER & SCINTO

1290 Avenue of the Americas

New York, NY 10104-3800

Telephone: (212) 218-2100

Facsimile: (212) 218-2200

Aventis Pharma S.A. may be served electronically using the following e-mail addresses:

dconde@fchs.com (lead counsel)

wsolander@fchs.com (back-up counsel)

jleonard@fchs.com (back-up counsel)

wmeier@fchs.com (back-up counsel)

Any questions concerning this paper may be directed to lead counsel listed below.

April 5, 2016

Respectfully submitted,

/Dominick A. Conde/

Dominick A. Conde (Reg. No. 33,856)  
Lead Counsel for Patent Owner  
FITZPATRICK, CELLA, HARPER & SCINTO  
Tel: (212) 218-2100

*Attorneys for Patent Owner,  
Aventis Pharma S.A.*

Back-up Counsel:

William E. Solander (*pro hac vice*  
pending)  
Jason A. Leonard (*pro hac vice*  
pending)  
Whitney L. Meier (Reg. No. 69,923)  
FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, NY 10104-3800  
(212) 218-2100

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.